Teva Pharmaceutical Industries Limited
5 Basel Street
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd. develops, produces and markets ethical drugs, generic drugs, and fine chemicals for the pharmaceutical industry and disposable products for hospitals and home care services.
1430 articles with Teva Pharmaceutical Industries Limited
It apparently began with a 2016 federal lawsuit. At that time, 20 state attorneys general filed a federal lawsuit alleging that six generic drug makers artificially inflated and manipulated prices for an antibiotic and an oral diabetes drug. The goal was to reduce competition.
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications
Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) today announced that the Food and Drug Administration (FDA) has approved TRUXIMA® (rituximab-abbs), a monoclonal antibody (mAb) biosimilar to RITUXAN®1 (rituximab) for the treatment of adult patients in three indications:
11/28/2018There has been another recall for blood pressure medications. This time Teva Pharmaceutical has issued a voluntary recall for combination forms of its blood pressure drug Amlodipine due to cancer-causing impurities discovered in the tablets.
Teva’s Generic Version of EpiPen® (Epinephrine Injection, USP) Auto-Injector 0.3 mg Now Available in Limited Quantity in the United States
Teva Pharmaceutical Industries today announced the release of limited doses of the FDA-approved generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg, in the US. Teva’s generic version of the EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg, and an additional supply of Teva’s generic version of the EpiPen® (epinephrine injection, USP) Auto-Injector, 0.3 mg is expected in 2019.
Allergan indicated that it “has shifted [its] priority from expanding the Waco site to investing significantly in our existing operations.” However, the company spokesperson said that Allergan “remains committed to our eye care business and operations in Waco.”
Revenues of $4.5 billion
Eli Lilly and Company and Pfizer presented complete results from a Phase III clinical trial of tanezumab in patients with osteoarthritis (OA) at the 2018 American College of Rheumatology/Association of Rheumatology for Health Professionals (ACR/ARHP) Annual Meeting in Chicago.
Part of the Trump Administration and the U.S. Food and Drug Administration (FDA)’s strategy to push down drug prices is to develop ways to increase competition. As such, the agency launched a Drug Competition Action Plan that has several components.
10/19/2018TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.
Bone-on-bone knee pain from osteoarthritis can be agonizing and often results in surgery. But for some patients, there is another therapy option gaining ground – engineered cartilage implants.
With a new wave of migraine medications now on the market from multiple drugmakers that block the calcitonin gene-related peptide receptor (CGRP-R), Express Scripts has chosen to back two medications and exclude a third from the list of drugs it will carry.
Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE® (glatiramer acetate injection) for the Treatment of Relapsing Forms of Multiple Sclerosis
Teva Pharmaceutical Industries Limited. (NYSE and TASE: TEVA) today announced safety and tolerability results representing 25 years of data from the open-label extension study of the original U.S. pivotal trial of COPAXONE® (glatiramer acetate injection) for the treatment of relapsing forms of multiple sclerosis (RMS).
Landmark strategic commercial collaboration expands the global footprint of the first-of-its-kind reproductive health test for women
Teva to Present New Data at 34th European Committee for Treatment and Research in Multiple Sclerosis Congress in Berlin
Teva Pharmaceutical Industries Ltd. today announced that new data on COPAXONE® (glatiramer acetate injection), a product for relapsing forms of multiple sclerosis (RMS), will be presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Berlin, October 10-12, 2018.
Teva Pharmaceutical Industries Ltd. announced today that it will release its third quarter 2018 financial results on Thursday, November 1, 2018 at 7:00 a.m. ET.
10/1/2018Here's a look at who shook things up in the world of pharma and biotech this week.
The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Emgality (galcanezumab-gnlm) for migraine prevention.
Teva Pharmaceutical Industries Ltd. today announced the exclusive first-to-file launch of a generic version of Cialis®1 (tadalafil) tablets (2.5 mg, 5 mg, 10 mg, 20 mg) in the U.S.
The past few days has had a flurry of activity in the industry with leadership changes. Let's take a look at some of those!